Prothena Corp Public (PRTA) Revenue (2013 - 2026)
Prothena Corp Public's quarterly Revenue came in at $51.1 million in Q1 2026, up 1706.36% year-on-year from $2.8 million in Q1 2025, and up 243157.14% quarter-over-quarter from $21000.0 in Q4 2025.
Prothena Corp Public has reported Revenue for 14 years, with the latest figure at $51.1 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 1706.36% year-over-year to $51.1 million; the trailing twelve-month figure through Mar 2026 stood at $57.9 million (down 57.99% YoY), and the FY2025 full-year result was $9.7 million, down 92.83% from the prior year.
- Revenue for Q1 2026 stood at $51.1 million, up from $21000.0 in the prior quarter.
- The five-year high for Revenue was $132.0 million in Q2 2024, with the low at $21000.0 in Q4 2025.
- Average Revenue over 5 years is $20.1 million, with a median of $2.2 million recorded in 2023.
- Year-over-year, Revenue tumbled 99.37% in 2023 and jumped 5556.0% in 2025.
- Tracing PRTA's Revenue over 5 years: stood at $49.9 million in 2022, then plunged by 99.37% to $316000.0 in 2023, then jumped by 571.84% to $2.1 million in 2024, then slumped by 99.01% to $21000.0 in 2025, then surged by 243157.14% to $51.1 million in 2026.
- The last three Revenue figures came in at $51.1 million (Q1 2026), $21000.0 (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Prothena Corp Public | 546.75 Mn | 217.29 Mn | - | 51.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.08 Mn |
| Dec 31, 2025 | 21,000.00 |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 4.42 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 2.12 Mn |
| Sep 30, 2024 | 970,000.00 |
| Jun 30, 2024 | 132.01 Mn |
| Mar 31, 2024 | 50,000.00 |
| Dec 31, 2023 | 316,000.00 |
| Sep 30, 2023 | 84.87 Mn |
| Jun 30, 2023 | 4.02 Mn |
| Mar 31, 2023 | 2.17 Mn |
| Dec 31, 2022 | 49.92 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Jun 30, 2022 | 1.31 Mn |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 1.17 Mn |
| Sep 30, 2021 | 139.17 Mn |
| Jun 30, 2021 | 60.07 Mn |
| Mar 31, 2021 | 160,000.00 |
| Dec 31, 2020 | 360,000.00 |
| Sep 30, 2020 | 157,000.00 |
| Jun 30, 2020 | 195,000.00 |
| Mar 31, 2020 | 141,000.00 |
| Dec 31, 2019 | 256,000.00 |
| Sep 30, 2019 | 205,000.00 |
| Jun 30, 2019 | 167,000.00 |
| Mar 31, 2019 | 186,000.00 |
| Dec 31, 2018 | 194,000.00 |
| Sep 30, 2018 | 255,000.00 |
| Jun 30, 2018 | 279,000.00 |
| Mar 31, 2018 | 227,000.00 |
| Dec 31, 2017 | 229,000.00 |
| Sep 30, 2017 | 219,000.00 |
| Jun 30, 2017 | 26.81 Mn |
| Mar 31, 2017 | 259,000.00 |
| Dec 31, 2016 | 171,000.00 |
| Sep 30, 2016 | 286,000.00 |
| Jun 30, 2016 | 333,000.00 |
| Mar 31, 2016 | 265,000.00 |
| Dec 31, 2015 | 307,000.00 |
| Sep 30, 2015 | 429,000.00 |
| Jun 30, 2015 | 278,000.00 |
| Mar 31, 2015 | 593,000.00 |
| Dec 31, 2014 | 2.01 Mn |
| Sep 30, 2014 | 1.49 Mn |
| Jun 30, 2014 | 15.12 Mn |
| Mar 31, 2014 | 32.23 Mn |
| Dec 31, 2013 | 167,000.00 |
| Sep 30, 2013 | 171,000.00 |
| Jun 30, 2013 | 167,000.00 |
| Mar 31, 2013 | 171,000.00 |